Pig cell transplant trial aims to stop severe low blood sugar in type 1 diabetes
NCT ID NCT06575426
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 27 times
Summary
This early-phase study tests a new treatment called OPF-310, which uses pig islet cells enclosed in a protective capsule, for people with unstable type 1 diabetes who still experience severe low blood sugar episodes despite using an automated insulin pump and continuous glucose monitor. The main goal is to see if the transplant is safe and can help control blood sugar without causing dangerous lows. About 13 adults aged 35 to 65 will receive an ascending dose of the cells and be monitored for a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois Hospital & Health Sciences System
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.